Trial Profile
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2009
Price :
$35
*
At a glance
- Drugs Atiprimod (Primary) ; Ursodeoxycholic acid
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Sep 2005 New trial record.